Locus-coeruleus function in normal elderly and AD risk (LEAD)

Brief description of study

(S,S)-[11C]Methylreboxetine ((S,S)-[11C]MRB) is a radioligand developed for positron emission tomography (PET) imaging of the brain adrenergic receptors. In ongoing clinical studies, 11C-MRB PET is currently being examined to determine whether the tracer has utility in the differential diagnosis and follow-up of Alzheimer’s disease risk and in evaluating the efficacy of preventive therapies. To enable the continued use of 11C-MRB and to confirm safety, it is important to determine the radiation exposure caused by such studies. The use of this tracer has been approved by the FDA since 2005. This tracer has been used for PET imaging of over 500 human studies with no major side effects. Before this tracer can be used in our main study, the dosimetry results need to be analyzed and reported locally prior to the start of the study.


Clinical Study Identifier: s20-00002
ClinicalTrials.gov Identifier: NCT04403165
Principal Investigator: Ricardo Miguel Osorio Suarez.
Other Investigator: Yu-Shin Ding.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.